Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib plus FOLFOX or XELOX vs placebo plus FOLFOX or XELOX in first-line metastatic colorectal cancer
2006-001194-14Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2006
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by AstraZeneca. Primary endpoints: overall survival and progression-free survival. Started Aug 2006; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2006-001194-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001194-14.